ACADIA Pharmaceuticals Inc (ACAD) Annual Income Statement (USD)
ACAD Quarterly Financials (USD)
Frequently Asked Questions About ACADIA Pharmaceuticals Inc (ACAD) Stock
ACADIA Pharmaceuticals Inc's (ACAD) last reported annual revenue was USD 726.44 Million.
ACADIA Pharmaceuticals Inc's (ACAD) annual revenue growth rate based on the revenue reported in the past 5 years is : 26.55%
ACADIA Pharmaceuticals Inc's(ACAD) is not profitable as of its last reported annual financials.
The net profit margin for ACADIA Pharmaceuticals Inc's(ACAD) from its laster reported year is -8.44%
The return on equity (ROE) for ACADIA Pharmaceuticals Inc's(ACAD) from its last reported annual financials is : -14.73%
The return on assets (ROA) for ACADIA Pharmaceuticals Inc's(ACAD) from its last reported annual financials is : -6.86%
The return on invested capital (ROIC) for ACADIA Pharmaceuticals Inc's(ACAD) from its last reported annual financials is : -20.10%
The Debt to Equity ratio for ACADIA Pharmaceuticals Inc's(ACAD) from its last reported annual financials is : 0.00%
The dividend yield for ACADIA Pharmaceuticals Inc's(ACAD) from its laster reported year is 0.00%
ACADIA Pharmaceuticals Inc's(ACAD) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACAD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
